Company Overview and News

1
Rebel Capital Inc. Announces Its Qualifying Transaction With Spektra Drilling Canada Inc.

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- Rebel Capital Inc. ("Rebel") (TSXV:RBL.P), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the "TSXV"), is pleased to announce it has entered into a binding amended letter of intent dated June 14, 2018 (the "Letter of Intent") with Spektra Drilling Canada Inc. ("Spektra"), a corporation existing under the laws of Canada.
JODRF LSG SIC AZX ALXDF ALT LSG ALTSF GDNDF

4
Updated Resource Contains Approximately 194,500 oz Indicated at 1.61 g/t Gold and 126,300 oz Inferred at 1.89 g/t Gold from Orenada Zones 2 and 4

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“Alexandria” or the “Company”) is pleased to announce that the newly completed mineral resource estimate at Orenada comprises 3,754,000 tonnes of indicated mineral resources with an average grade of 1.61 grams of gold per tonne (“g/t Au”) for 194,522 ounces of contained gold and 2,079,000 tonnes of inferred mineral resources with an average grade of 1.
AZX ALXDF MALRY MALRF MIN

28
Alexandria Announces New Corporate Direction

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- Following the results announced today regarding the 2017 drilling plan at Alexandria Minerals Corporation’s (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) Orenada project undertaken under the direction of former CEO, Eric Owens, who was terminated for cause, the Company is announcing a new corporate direction to build value for all shareholders.
AZX ALXDF ELD AEM EGO

0
Alexandria Intersects New Gold Zones West of Orenada with up to 1.80 metres @ 36.62 g/t Gold

2018-04-09 globenewswire
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) is pleased to announce the assay results from the first eight diamond drill holes from it’s 2018 winter drill program on new areas west and north-west of the Company’s Orenada property in Val d’Or, Quebec. For the 2018 winter program the company drilled 34 holes for 12,072.
GLVMF AZX ALXDF GZZ

0
Alexandria Minerals Sets the Record Straight on Eric Owens’ Termination and Unauthorized Financing Scheme

2018-03-28 globenewswire
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- On February 13, 2018, the Board of Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) terminated Eric Owens as Chief Executive Officer for cause because, among other things, he engaged in an unauthorized financing scheme and accepted investors’ funds into his personal lawyer’s trust account. These funds were illicitly obtained without the Board’s approval and solicited to a limited network of investors selected by Mr.
AZX ALXDF

0
Alexandria Minerals Sets Date for Requisitioned Shareholder Meeting

2018-03-16 globenewswire
TORONTO, March 16, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) announces it will hold a special meeting of shareholders (the “Meeting”) on July 24, 2018.
AZX ALXDF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:AZX / Alexandria Minerals Corp on message board site Silicon Investor.

AZX Anzex